At Loyal we’re developing the first FDA-approved drugs explicitly intended to extend lifespan and healthspan, and being first means charting new waters.

On the path to FDA approval, we must run a clinical trial that objectively and robustly demonstrates that our drug extends dogs’ healthy lifespan, and does so safely. Because no one has developed a dog — or human — longevity drug before, we are building the path to FDA approval largely from scratch.

Last week we learned from the FDA that Loyal received protocol concurrence for our companion dog longevity study — likely the first time the FDA has given their blessing to a longevity clinical trial. Our regulatory expert Karen Greenwood weighs in on what this means for Loyal, for the field of aging, and for dogs everywhere.

Loyal Founder and CEO, Celine Halioua, introduces the newest addition to our Board of Directors

This month’s recap includes snapshots about research into alternative forms of treatment for aging dogs: supplements and cannabis. We also learned about the dog-human bond, both from rescue dog statistics and and a test of dog love between their humans and food.

Scientists have revealed insights into your dog’s super-powerful nose. They’ve also uncovered new potential solutions for skin issues, revealed information about hearing loss in aging dogs, and offered an in-depth review into how your habits and activity can affect your dog’s weight.

Dive into highlights from the animal health and veterinary space this month. Nutritious insect protein, the link between cancer and pollution, and happy tears are just a few of the month’s most interesting discoveries.

Do dogs “see” with their noses? Can my dog feel guilt? Can dogs catch monkeypox from their owners? Find out in this month’s review on canine science research.

Why I’d love to see general practitioners participate in clinical research: 5 compelling reasons from a former GP